Skip to content
Open access · OA via Europe PMC

Genetically proxied glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor pathway modulation is associated with favorable aging phenotypes: a drug-target Mendelian randomization study.

Li J, Xu X, Wang N, Lu Y, Wang B.

Cardiovascular diabetology · 2026

Abstract

<h4>Background</h4>Glucagon-like peptide-1 receptor (GLP1R) agonists and dual glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor (GIPR/GLP1R) agonists are established treatments for diabetes and obesity, but their potential effects on biological aging remain uncertain.<h4>Methods</h4>In this drug target Mendelian randomization study, we assessed the associations of genetically proxied modulation of GLP1R, GIPR, and dual GIPR/GLP1R pathways with four aging phenotypes, including frailty index, phenotypic age (PhenoAge) acceleration, telomere(definition) length, and longevity.<h4>Results</h4>Glycated hemoglobin (HbA1c) lowering via GIPR, modeling the glucose-lowering effect of variants in GIPR loci, was consistently associated with a lower frailty index (primary dataset: β = - 0.10 [95% CI: - 0.18, - 0.02]; replication dataset: - 0.14 [- 0.27, - 0.01]), reduced PhenoAge acceleration (primary: - 0.82 [- 1.17, - 0.48]; replication - 1.04 [- 1.81, - 0.27]), longer telomere length (primary: 0.06 [0.003, 0.11]; replication: 0.09 [0.002, 0.19]), and greater odds of longevity (primary: odds ratio [OR] = 2.90 [95% CI: 1.93, 4.36]; replication: 6.54 [2.92, 14.65]). Body mass index (BMI) lowering via GIPR, modeling appetite-suppressing and weight-reducing effects of variants, was associated with a lower frailty index (primary: - 0.07 [- 0.13, - 0.01]; replication: - 0.19 [- 0.35, - 0.04]) and higher odds of longevity (primary: 2.11 [1.22, 3.66]). In contrast, HbA1c lowering via GLP1R was associated exclusively with longevity (primary: OR = 3.72 [2.25, 6.18]; replication: 16.53 [4.28, 63.80]), whereas BMI lowering via GLP1R was not associated with any aging phenotype. Analyses of dual GIPR/GLP1R yielded results broadly similar to those for GIPR, with the exception of a null effect on frailty index.<h4>Conclusions</h4>Genetically proxied HbA1c- and BMI-lowering effects through GLP1R- and GIPR-related pathways were favorably associated with aging phenotypes, with broader associations observed for HbA1c lowering. Further clinical studies are warranted to clarify the relevance of these pathways to healthy aging.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
Europe PMC
DOI
10.1186/s12933-026-03304-y
Canonical
link ↗
Fetched
2026-10-09 MST

Cite this

APA
J, L., X, X., N, W., Y, L., &amp; B., W. (2026). Genetically proxied glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor pathway modulation is associated with favorable aging phenotypes: a drug-target Mendelian randomization study. <em>Cardiovascular diabetology</em>. https://doi.org/10.1186/s12933-026-03304-y
Vancouver
J L, X X, N W, Y L, B. W. Genetically proxied glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor pathway modulation is associated with favorable aging phenotypes: a drug-target Mendelian randomization study. Cardiovascular diabetology. 2026. doi:10.1186/s12933-026-03304-y.
BibTeX
@article{li2026Geneti, title = {Genetically proxied glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor pathway modulation is associated with favorable aging phenotypes: a drug-target Mendelian randomization study.}, author = {Li J and Xu X and Wang N and Lu Y and Wang B.}, journal = {Cardiovascular diabetology}, year = {2026}, doi = {10.1186/s12933-026-03304-y}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings